Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CYP
vs
S
S&P/ASX 300
CYP
Over the past 12 months, CYP has underperformed S&P/ASX 300, delivering a return of -95% compared to S&P/ASX 300's 3% drop.
Stocks Performance
CYP vs S&P/ASX 300
Performance Gap
CYP vs S&P/ASX 300
Performance By Year
CYP vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cynata Therapeutics Ltd
Glance View
Cynata Therapeutics is a biotech company that develops cell-based medicines, mainly therapies built from mesenchymal stem cells, or MSCs. Its core idea is to make these cells from a master cell line rather than relying on donors one batch at a time. That matters because it is meant to give drug developers a more consistent and scalable source of cells for testing and treatment. The company does not sell a mass-market product. It earns money by developing its cell therapy platform, advancing its own product candidates, and working with research partners and pharmaceutical companies that want to use its technology in clinical development. Its customers and counterparties are mainly hospitals, researchers, drug developers, and potential license or collaboration partners in regenerative medicine. What makes Cynata different is its role as a technology supplier in the stem cell supply chain. Instead of being a broad drug maker, it focuses on the cell source and manufacturing method that other therapies can be built on. That gives it a business tied to both drug development and platform licensing, with value coming from making high-quality therapeutic cells more practical to produce and use.
